Search clinical trials for: Anlotinib Tislelizumab Irinotecan

Total 3251 results

Wuhan Union Hospital, China

Not yet recruiting

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Carcinoma | Intrahepatic Cholangiocarcinoma | Gallbladder Cancer | Immunotherapy | Tislelizumab | Surufatinib | Angiogenesis Inhibitors | Antineoplastic Agents, Immunological
UNICANCER

Recruiting

Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions (HESTIA)

Hepatocellular Carcinoma by BCLC Stage

France
University Health Network, Toronto
Novartis

Terminated

A Study of Nilotinib in Growing Vestibular Schwannomas

Growing Vestibular Schwannomas

Canada
Novartis Pharmaceuticals

Completed

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib (MACS1428)

Chronic Myelogenous Leukemia in Chronic Phase

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. (NILOMEL)

Stage IV Melanoma | Stage III Melanoma | Amplification | Malignant Skin Melanoma T0

France
BeiGene

Not yet recruiting

Phase 1 First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumor
BeiGene

Active, not recruiting

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer

Colorectal Cancer

China
BeiGene

Completed

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Advanced Solid Tumors

China
Zhejiang Cancer Hospital

Active, not recruiting

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

Lung Cancer, Small Cell

China
National Taiwan University Hospital

Completed

Nilotinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

Patients Who Have Received Allo-HSCT

Taiwan
Georgetown University

Completed

Nilotinib in Cognitively Impaired Parkinson Disease Patients 001

Parkinson's Disease | Parkinson's Disease Dementia | Diffuse Lewy Body Disease

United States
Seoul St. Mary's Hospital
Novartis

Unknown

Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib (AMICAN)

Chronic Myeloid Leukemia

Korea, Republic of
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
BeiGene

Recruiting

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Melanoma | Renal Cell Carcinoma | Urothelial Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma

Endometrial Carcinoma

China
Fudan University

Not yet recruiting

Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis

Colorectal Cancer | Liver Metastases

China
Generic Devices Consulting, Inc.
Biocompatibles UK Ltd

Terminated

Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer (PARAGON)

Unresectable Metastatic Colo-rectal Cancer

United States
OHSU Knight Cancer Institute
Genentech, Inc.; OSI Pharmaceuticals

Terminated

Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

United States
Taizhou Hospital

Not yet recruiting

Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell (SCLC)

SCLC | Maintenance Treatment
Army Medical Center of PLA

Recruiting

A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Esophageal Squamous Cell Carcinoma

China
Ningbo Medical Center Lihuili Hospital

Recruiting

The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study

Non-Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients

Liver Dysfunction

China
Tianjin Medical University Cancer Institute and...

Recruiting

Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer

Small Cell Lung Cancer Limited Stage

China
University of Southern California
National Cancer Institute (NCI); Ipsen

Withdrawn

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Locally Advanced Unresectable Gastric Adenocarcinoma | Metastatic Unresectable Gastric Adenocarcinoma

United States
University of Southern California

Completed

Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan

Adenocarcinoma | Gastric Cancer

United States
Samsung Medical Center

Completed

Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding

Stomach Neoplasms

Korea, Republic of
Jill M Kolesar
National Cancer Institute (NCI); Novartis

Recruiting

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Metastatic Melanoma | BRAF Gene Mutation

United States
Novartis Pharmaceuticals

Completed

Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line (NOFRETETE)

Chronic Myeloid Leukemia

Germany
Hospital for Special Surgery, New York
Novartis Pharmaceuticals; Rudolph Rupert Scleroderma Program

Completed

Nilotinib in the Treatment of Systemic Sclerosis

Systemic Sclerosis

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

Healthy

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi

China
US Oncology Research
Bristol-Myers Squibb; Pfizer

Active, not recruiting

PhII ICb With/Without Erbitux in MBC Pts (CA225200)

Metastatic Breast Cancer

United States
University of Arizona
National Cancer Institute (NCI)

Completed

Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer

Breast Cancer

United States
Emory University
Ipsen; Taiho Oncology, Inc.

Recruiting

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Gastric Adenocarcinoma | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IV Gastric Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage... and other conditions

United States
Zhejiang Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Innovent Biologics (Suzhou)...

Unknown

The Efficacy and Safety of Antinib Hydrochloride Combined With Sindilumab in Advanced NSCLC Patients

NSCLC

China
Immune-Onc Therapeutics

Completed

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

Advanced Solid Tumor

China
Novartis Pharmaceuticals

Completed

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment (MACS0999)

Chronic Myelogenous Leukemia

United States, Canada
National Cancer Institute (NCI)

Completed

17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
BeiGene

Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

United States, New Zealand, Australia, China
BeiGene

Active, not recruiting

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

Solid Tumor

Australia, United States
University Hospital, Rouen

Completed

Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial

Esophageal Neoplasms

France
Guangdong Association of Clinical Trials

Unknown

Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment

Small Cell Lung Cancer

China
National Cancer Center, Korea

Unknown

Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan

Colorectal Neoplasms | Secondary

Korea, Republic of
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer

Breast Cancer

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Irinotecan in Treating Aging Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Cancer Advances Inc.

Completed

Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma (CC6)

Colorectal Cancer
Texas Children's Cancer Center

Completed

Irinotecan in Treating Children With Refractory or Progressive Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States
New Approaches to Brain Tumor Therapy Consortium
National Cancer Institute (NCI)

Completed

Irinotecan in Treating Patients With Recurrent Malignant Glioma

Brain and Central Nervous System Tumors

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer
Northwestern University
National Cancer Institute (NCI)

Completed

Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer

Breast Cancer

United States

Search clinical trials for: Anlotinib Tislelizumab Irinotecan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations